Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars
Francesca Prignano, Jaeyun Choi, Burkhard Pieper, et al.
Expert Opinion on Biological Therapy (2020) Vol. 21, Iss. 1, pp. 75-80
Open Access | Times Cited: 12

Showing 12 citing articles:

Bimekizumab versus Adalimumab in Plaque Psoriasis
Richard B. Warren, Andrew Blauvelt, Jerry Bagel, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 2, pp. 130-141
Open Access | Times Cited: 168
Portuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy – a delphi methodology
Tiago Torres, Sofia Magina, Maria João Paiva Lopes
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation
Eun Sil Kim, Hyangah Chon, Yiyoung Kwon, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 4, pp. 460-467
Open Access | Times Cited: 3
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
Francesco Bellinato, Paolo Gisondi, Elena Jane Mason, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 6, pp. 1303-1311
Open Access | Times Cited: 10
A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis
Yu Chen, Furen Zhang, Yangfeng Ding, et al.
International Immunopharmacology (2022) Vol. 112, pp. 109248-109248
Closed Access | Times Cited: 6
Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial
А. В. Самцов, А. Л. Бакулев, В. Р. Хайрутдинов, et al.
PLoS ONE (2022) Vol. 17, Iss. 2, pp. e0263214-e0263214
Open Access | Times Cited: 5
The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance
Nicola Humphry
EMJ Gastroenterology (2022), pp. 2-10
Open Access | Times Cited: 3
P92 Efficacy and safety of infliximab biosimilars in the treatment of patients with moderate-to-severe psoriasis

British Journal of Dermatology (2024) Vol. 191, Iss. Supplement_3
Closed Access
A Randomized, Double-Blind Phase III Study to Demonstrate the Clinical Similarity of Biosimilar SCT630 to Reference Adalimumab in Chinese Patients with Moderate to Severe Plaque Psoriasis
Yu Chen, Gang Wang, Furen Zhang, et al.
SSRN Electronic Journal (2022)
Closed Access | Times Cited: 1
Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients
Flavia Manzo Margiotta, Alessandra Michelucci, Salvatore Panduri, et al.
JEADV Clinical Practice (2023) Vol. 3, Iss. 1, pp. 65-75
Open Access
Estimation of patients with psoriasis potentially eligible and currently untreated with biological drugs in Italy
Luca Degli Esposti, Valentina Perrone, Melania Dovizio, et al.
Italian Journal of Dermatology and Venereology (2023) Vol. 158, Iss. 6
Closed Access
Biosimilars approved for psoriasis treatment in Europe
Ardea Milidrag, Maja Lačković, Ivana Dimić, et al.
PONS - medicinski casopis (2023) Vol. 20, Iss. 2, pp. 71-78
Open Access
Page 1

Scroll to top